Safety in the administration to pregnant or lactating women has not been established. Administration to these patients should be considered only if the expected therapeutic effect is judged to outweigh any possible risk. [In an animal (rats) study where a large dose of monoammonium glycyrrhizinate was administered there were findings of kidney malformation and the like.]
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
